CervoMed's Neflamapimod Shows Potential to Reverse DLB Progression

CervoMed Inc. presented MRI analyses at the 2026 AAN Annual Meeting, demonstrating that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies (DLB). These findings from further analysis of the RewinD-LB Phase 2b clinical trial are consistent with preclinical data, suggesting that basal forebrain atrophy in DLB might be reversible. The company believes neflamapimod acts on the underlying cause of DLB and plans to incorporate this MRI technology into a planned Phase 3 trial in DLB patients, subject to financing, later this year.